Perhaps you think it's impossible to score another 1,000% gain off this "tech titan" stock. Think again. An unusual strategy lets you virtually "recreate" gains off the biggest companies you thought had come and gone. CLICK HERE to see how it works.
A Sector Where Few Dare to Go…
by Robert Williams, Publisher
Thursday, October 1, 2009
Have you heard the chatter coming out of the retail sector? Last week, Citigroup upgraded Macy’s (NYSE: M) to a “Buy.” And yesterday, Moody’s raised its broad outlook on U.S. retailers from “Negative” to “Stable.”
The respective upgrades serve as further proof that the economy is improving, which puts the onus on the Fed to figure out an exit strategy.
The Fed used unprecedented measures, including lowering short-term interest rates to near zero and buying a wide range of securities, to stabilize financial markets.
However, soon it’ll be time for Bernanke’s gang to reverse course. That means raising interest rates, withdrawing support from the credit markets and selling the securities it accumulated.
And when news of such action hits the wire, stocks – especially retailers – will likely be under extraordinary buying pressure.
That’s why Louis, who’s developing a habit calling turnarounds before they happen, is positioning himself ahead of the Fed’s inevitable announcement in his latest article.
Ahead of the tape,
Robert Williams
- The Frontline of the Global Recovery
- CEOs: Put Your Money Where Your Mouth Is
- The Healthcare Debate: We’ll Stick to Earning Profits
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
In addition to once being a full-time trader of equities and equity derivatives, Robert Williams has also served as the lead financial analyst for a Forbes top-50 private corporation and an analyst for the endowment of a major academic institution.
Investment U RSS Feed